Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous Mainz Biomed Enters into Technology Partnership with EDX Medical Group 29.04.2025 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement.  Mainz Biomed Enters into Technology Partnership with EDX Medical Group

BERKELEY, US and MAINZ, Germany – April 29, 2025 – Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases.

Under the agreement, EDX Medical will access Mainz Biomed’s molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK.

“We are delighted to join forces with EDX Medical Limited to improve access to high-quality cancer diagnostics in the UK,” said Guido Baechler, Chief Executive Officer of Mainz Biomed. “By merging our expertise in molecular diagnostics with EDX Medical’s excellent capabilities, we can provide a highly reliable and meaningful contribution to early cancer detection and prevention.”

Dr Mike Hudson, CEO of EDX Medical, said: " We are dedicated to making the very best diagnostic tests available to patients and healthcare professionals and are continuously looking to improve the performance of cancer testing by incorporating molecular biomarkers that can transform early cancer detection. We are delighted to form this technology partnership which will help us achieve this aim.”

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About Mainz Biomed NV

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert is marketed across Europe. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.